(NASDAQ: BDSI), a specialty pharmaceutical company, has announced positive results of a completed pharmacokinetic study examining the effects of multiple BEMA Buprenorphine/Naloxone (BNX) films administered concurrently.
The study is a part of the United States Food and Drug Administration recommended programme for a New Drug Application for BNX.
Eight of the 16 mice were subjected to bilateral olfactory nerve transection (BNX
group), and the remaining 8 mice underwent a sham surgery (sham group).
The other grade, BNX
BetaPP-N, contains a higher level of beta-nucleant and is also designed for use at 2% to 3% in situations where weak alpha-nucleating agents, such as certain pigments and additives, may be present in the PP and could interfere with beta-nucleation.
Swedish fingerprint technology developer Precise Biometrics AB has signed an agreement with identity management solutions provider BNX
Currently in development and scheduled for release this year are the firm's BLS 1710 benzotriazole light stabilizer; BNX
1035 hindered phenolic antioxidant; and BLS 1200 benziphenone light stabilizer.
21 December 2011 - BioDelivery Sciences International Inc (NASDAQ:BDSI) unveiled on Tuesday encouraging results from its confirmatory study, BNX-102, evaluating the pharmacokinetics of its BEMA Buprenorphine/Naloxone (BNX
) formulation compared to Suboxone.
TELECOMWORLDWIRE-23 June 2003-Precise Biometrics AB and BNX
Systems team for product integration(C)1994-2003 M2 COMMUNICATIONS LTD http://www.m2.com
Mayzo has introduced BNX
1035, a powdered phenolic equivalent to Irganox 1035.
Looking to broaden its position in antioxidants, Mayzo (which imports Taiwanese equivalents of Irganox 1010 and 1076) has launched BNX
1000, a synergistic liquid blend of a hindered phenolic and four other antioxidants.
Systems has released an upgrade to their Authenticated Sign-On.
Systems is a leading provider of enterprise identity and access management solutions.